Humacyte (HUMA) Director Keith A. Jones Buys 30,000 Shares

What Happened
Keith A. Jones, a director of Humacyte, purchased 30,000 shares of Humacyte, Inc. (HUMA) in an open‑market transaction on August 17, 2026. The weighted average price was $0.59 per share (range $0.590–$0.596), for a total reported purchase value of $17,820. This was a purchase (buy), which investors often treat as a more informative signal than routine sales.

Key Details

• Transaction date: August 17, 2026; Form 4 filed August 19, 2026 (within the typical 2‑business‑day reporting window).
• Transaction type/code: P = Purchase (open‑market or private purchase as reported).
• Shares purchased: 30,000 at a weighted average price of $0.59; per‑share prices ranged $0.590–$0.596. Total = $17,820.
• Shares owned after the transaction: not specified in the information provided here (see the full Form 4 for aggregate beneficial ownership).
• Footnote: The reported price is a weighted average; the filer offers to provide, upon request, the breakdown of the number of shares bought at each separate price within the stated range.

Context

• This is a straightforward open‑market purchase by a company director. Purchases are generally viewed as a positive signal of confidence, though they don’t prove future performance.
• No options exercises, gifts, or tax‑withholding events are involved in this transaction.
• For full details (exact post‑transaction holdings, trading plan disclosures, or further footnotes), consult the complete Form 4 filing (Accession No. 0001193125-26-356847).